The emergence of immunotherapy has dramatically changed how non–small cell lung
cancer is treated, and longer survival is now possible for some patients, even those with …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …

Background Although EGFR mutant tumors exhibit low response rates to immune
checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; …

Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …

Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …

Abstract Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade
has been approved as the standard-of-care for the treatment of non-small cell lung cancer …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Purpose: Protein expression in formalin-fixed, paraffin-embedded tissue is routinely
measured by IHC or quantitative fluorescence (QIF) on a handful of markers on a single …